

Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

Received: 27 February 2022

Accepted: 19 April 2023

Published online: 26 May 2023

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset ($n = 115$) identified novel candidate genes, including *FADS1* at 11q12 and *ELF5* at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking ($P_{\text{interaction}} = 0.0058$). These findings provide new insights into the etiology of lung adenocarcinoma in individuals from East Asian populations, which could be important in developing translational applications.

Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and accounts for approximately 40% of lung cancer incidence worldwide^{1–3}. In studies drawn from East Asian (EA) ancestry, LUAD has been the predominant histologic subtype among females² and has replaced squamous cell carcinoma as the most common subtype in males^{4,5}. Well established risk factors, namely, tobacco smoking, certain environmental/occupational exposures and lifestyle factors, and family history, contribute to the risk of LUAD^{6–8}. In addition, multiple genome-wide association studies (GWAS) have identified at least 24 susceptibility loci for LUAD that achieved genome-wide significance, many drawn from studies in EA^{9–15} and European (EUR)^{16–23} populations, as well as multi-ancestry meta-analyses^{24,25}. Of these, 12 loci have been reported at genome-wide significance in GWAS of either never-smokers^{9,11–13} or smokers and nonsmokers combined^{10,14,15,24} in EA populations while another two loci were suggested in a multi-ancestry meta-analysis²⁴. We estimated that the known susceptibility variants account for only 13% of the estimated familial risk in EA populations.

Accordingly, larger studies are needed to investigate the underlying architecture of susceptibility to LUAD in never-smokers and individuals with a history of smoking and in different ancestral populations. The importance of multi-ancestry analyses is further highlighted by reports of susceptibility loci showing association for LUAD in EA but not in EUR populations¹³.

In the current study, we conducted a two-stage GWAS meta-analysis in EA populations using unpublished and previously published data from four studies: the Female Lung Cancer Consortium in Asia (FLCCA), Nanjing Lung Cancer Study (NJLCS)^{10,24}, National Cancer Center Research Institute (NCC) and Aichi Cancer Center (ACC), with 11,753 cases and 30,562 controls in the discovery set and 9905 cases and 120,114 controls in the replication set. A multi-ancestry meta-analysis of EA and EUR studies^{16,22} (from the International Lung Cancer Consortium, ILCCO) was performed to identify variants shared by both populations. We also investigated the heterogeneity of effect sizes for susceptibility variants identified in EA and EUR populations^{16,22} and

✉ e-mail: jianxin.shi@nih.gov; qingl@mail.nih.gov

obtained genome-wide estimates of effect-size correlation. Finally, we evaluated the genetic architecture²⁶ of LUAD, characterized by the number of susceptibility variants and their effect size distribution after normalizing allele frequencies, to investigate the accuracy of genetic risk prediction in the future GWAS in EA populations with increased sample sizes.

Results

Two-stage GWAS meta-analysis of LUAD in East Asian populations

For the discovery set, we performed a fixed-effect meta-analysis (11,753 cases and 30,562 controls) drawn from EA studies (Table 1, Supplementary Table 1). Details of quality control, imputation and post-imputation filtering are described in Methods. Variants with an imputation quality score ≥ 0.5 and minor allele frequency (MAF) ≥ 0.01 were included for meta-analysis. The estimated genetic correlation between LUAD in never-smokers and individuals with a history of smoking was $r_g = 0.81$ (s.e. = 0.16) using linkage disequilibrium (LD) score regression (LDSC)²⁷, which enabled the primary meta-analysis to include the two groups. LDSC analysis suggested little evidence of residual population stratification (LDSC intercept = 1.03). We identified 14 loci achieving genome-wide significance $P < 5 \times 10^{-8}$ (Supplementary Table 2); two were novel at 2p23.3 (rs682888, OR = 0.89, $P = 4.94 \times 10^{-10}$) and at 7q31.33 (rs4268071, OR = 1.39, $P = 7.27 \times 10^{-10}$). In meta-analysis performed separately for males and females, and for never-smokers and individuals with a history of smoking, no further loci achieved genome-wide significance.

In the replication phase, we selected 38 lead variants with $P < 10^{-5}$ in the discovery data that were not previously reported as genome-wide significant in either EA or EUR populations and genotyped them in an independent data set of 9905 LUAD cases and 120,114 controls from a Japanese population (Table 1, Supplementary Table 1). After combining the discovery and the replication data, we identified a total of 10 novel loci achieving genome-wide significance and a novel variant on the locus at 15q21.2 that was previously reported in EUR populations¹⁶ (Table 2, Manhattan plot in Fig. 1, and regional association plots in Supplementary Fig. 1).

Conditional analysis using GWAS summary statistics suggested two additional susceptibility variants rs13167280 (OR = 1.29, $P = 4.07 \times 10^{-13}$) and rs62332591 (OR = 0.87, $P = 3.21 \times 10^{-8}$) in the locus at 5p15.33 (Table 3, Supplementary Fig. 2); both are in modest LD with previously reported secondary variants in EA populations²⁸ ($R^2 = 0.27$ between rs13167280 and rs10054203;²⁸ $R^2 = 0.19$ between rs62332591 and rs10054203²⁸). Variant rs12664490 (OR = 0.81, $P = 1.24 \times 10^{-10}$) was conditionally significant in a locus previously reported in EA at 6p21.1 (Table 3, Supplementary Fig. 3), adding another novel variant (12 novel variants in total).

A previous multi-ancestry meta-analysis conducted by Dai et al.²⁴ that included Chinese samples and EUR samples from the ILCCO study

identified three SNPs for LUAD, one of which achieved genome-wide significance and the other two were suggestive in their analysis restricted to the Chinese subgroup²⁴ (see Supplementary Table 3). In the meta-analysis of the Chinese samples in Dai et al.²⁴ with our independent EA samples, all three variants exceeded the threshold of genome-wide significance without issues of heterogeneity (Supplementary Table 3).

Overall, our study identified 12 novel susceptibility variants bringing the total to 28 genetic variants at 25 loci that have been identified to date in EA populations (Supplementary Table 4, Fig. 1). Assuming a familial risk estimate of 1.84 for first-degree relatives²⁹, the 25 independent susceptibility variants for LUAD (Supplementary Table 4) captured 16.2% of the familial relative risk in EA populations. Moreover, we found no evidence that the SNP associations differed between the samples from the Mainland of China and those from outside of the Mainland of China, or between Han Chinese and Japanese, the two largest ancestry populations in our study (Supplementary Table 5).

We further examined whether the novel variants identified in this study were associated with smoking behaviors (i.e., smoking status, cigarettes per day, initiation age and cessation) or chronic obstructive pulmonary disease in the Biobank Japan Project³⁰ (BBJ). We found no evidence that these variants were implicated in these traits in this cohort (Supplementary Table 6). A previous GWAS in EUR populations found variants (e.g., rs55781567) at the 15q25.1 *CHRNA5* locus associated with tobacco smoking and lung cancer risk only in individuals with a history of smoking (OR = 1.33, $P = 1.83 \times 10^{-78}$, MAF = 0.39)^{16,18,19,31}. However, this variant did not achieve genome-wide significance in our EA data (OR = 1.37, $P = 0.001$ for individuals with a history of smoking; OR = 1.05, $P = 0.44$ for never-smokers), likely because of a low MAF = 0.03, and no other variant in LD with this SNP showed a substantial association.

Fine mapping and functional analyses of GWAS loci

To prioritize candidate variants for functional follow-up from each of the LUAD GWAS loci, we performed Bayesian fine mapping using FINEMAP³² (Methods). Fine mapping of the genome-wide significant loci from the discovery set nominated 95% credible set variants for 9 loci with a median of 63 variants per locus (Supplementary Data 1). For the 12 novel variants identified from the combined discovery and replication datasets as well as conditional analysis, we then performed variant annotation analysis. High-LD variants for these signals ($R^2 \geq 0.8$ with the lead SNP in the 1000 Genomes, phase 3, EA) included those located in predicted promoters or enhancers in lung tissues/cells (RegulomeDB³³, Haploreg³⁴ v4.1, and FORGE2;³⁵ Supplementary Data 2), which can be tested in future experimental studies.

To further characterize the functionality of the prioritized susceptibility genes that could explain the new GWAS loci, eQTL colocalization and transcriptome-wide association study (TWAS) analyses

Table 1 | Demographic characteristics of the subjects in the discovery and the replication datasets for a GWAS of lung adenocarcinoma in East Asians

	Discovery ^a		Replication ^b		Combined	
	Cases	Controls	Cases	Controls	Cases	Controls
Male	4021 (34%)	11,609 (38%)	5650 (57%)	62,596 (52%)	9671(45%)	74,205 (49%)
Female	7732 (66%)	18,953 (62%)	4255 (43%)	57,518 (48%)	11,987 (55%)	76,471 (51%)
Individuals with smoking history	3751 (32%)	9780 (32%)	6108 (62%)	58,430 (49%)	9859 (46%)	68,210 (45%)
Never-smokers	8002 (68%)	20,782 (68%)	3797 (38%)	61,684 (51%)	11,799 (54%)	82,466 (55%)
Total	11,753	30,562	9905	120,114	21,658	150,676

^aThe discovery dataset includes 4438 cases and 4544 controls from the FLCCA study, 1923 cases and 3544 controls from the NJLCS study, 3921 cases and 19,910 controls from the NCC study and 1471 cases and 2564 controls from the ACC study.

^bThe replication dataset consists of new candidate variant genotyping conducted in Japanese study LUAD subjects by the NCC study center and controls from the BioBank Japan. More details can be found in Supplementary Table 1 and Methods.

Table 2 | Novel genetic variants associated with lung adenocarcinoma in East Asians

Chr	BP	SNP	Genes	Eff/Ref	EAF	Discovery		Replication		Combined	
						OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
3	138570011	rs137884934	<i>PIK3CB</i>	T/C	0.09	0.81(0.74,0.89)	6.33×10^{-6}	0.80(0.76,0.85)	1.88×10^{-15}	0.80(0.77,0.84)	6.21×10^{-20}
2	25757709	rs682888	<i>DTNB</i>	C/T	0.47	0.89(0.86,0.93)	4.94×10^{-10}	0.91(0.88,0.94)	1.57×10^{-10}	0.90(0.88,0.92)	5.96×10^{-19}
11	61581656	rs174559	<i>FADS1</i>	A/G	0.39	0.91(0.88,0.94)	6.10×10^{-7}	0.91(0.89,0.94)	6.22×10^{-9}	0.91(0.89,0.93)	1.93×10^{-14}
15	49757466	rs17467682 ^a	<i>FGF7, SECISBP2L</i>	G/A	0.31	0.91(0.87,0.95)	2.46×10^{-6}	0.90(0.88,0.93)	2.30×10^{-9}	0.91(0.88,0.93)	2.81×10^{-14}
10	126324209	rs10901793	<i>FAM53B, METTL10</i>	A/G	0.30	1.10(1.06,1.14)	3.14×10^{-7}	1.07(1.04,1.10)	1.03×10^{-5}	1.08(1.06,1.11)	3.04×10^{-11}
7	124373384	rs4268071 ^b	<i>GPR37</i>	T/G	0.04	1.39(1.25,1.54)	7.27×10^{-10}	NA	NA	1.39(1.25,1.54)	7.27×10^{-10}
6	53389995	rs531557	<i>GCLC</i>	T/A	0.60	0.90(0.87,0.94)	7.73×10^{-7}	0.94(0.91,0.97)	8.49×10^{-5}	0.93(0.90,0.95)	9.25×10^{-10}
19	725066	rs116863980	<i>PALM</i>	A/G	0.06	1.31(1.16,1.47)	7.94×10^{-6}	1.17(1.09,1.26)	2.50×10^{-5}	1.21(1.14,1.29)	2.63×10^{-9}
15	56454223	rs764014	<i>RFX7</i>	G/A	0.47	0.91(0.88,0.95)	5.75×10^{-7}	0.95(0.92,0.98)	7.36×10^{-4}	0.94(0.91,0.96)	7.73×10^{-9}
4	44174404	rs117715768	<i>KCTD8</i>	T/C	0.06	1.24(1.14,1.34)	4.48×10^{-7}	1.10(1.04,1.17)	1.28×10^{-3}	1.15(1.09,1.21)	2.45×10^{-8}
4	157894892	rs1373058	<i>PDGFC</i>	A/T	0.57	1.10(1.05,1.15)	8.55×10^{-6}	1.06(1.03,1.09)	3.60×10^{-4}	1.07(1.05,1.10)	3.86×10^{-8}

All *p* values are nominal and two-sided.

^ars71467682 is in weak LD with rs77468143 ($R^2 = 0.27$ in EA) that was previously reported to be associated with LUAD in EUR populations¹⁶.

^bReplication data not available.




Fig. 1 | Manhattan plot for GWAS meta-analysis of lung adenocarcinoma in East Asians. The *x*-axis represents chromosomal location, and the *y*-axis represents $-\log_{10}(p\text{-value})$. All *p* values were two-sided and not adjusted for multiple testing. The red horizontal line denotes the *p* value threshold for declaring genome-wide significance at 5×10^{-8} . For each box, red text represents a novel variant (12 novel variants, including the lead variants from 10 novel loci, rs12664490 by conditional analysis at 6p21.1, a locus previously reported in East Asians, and rs17467682 at 15q21.2, a locus previously reported in Europeans); black text represents a previously reported association (16 variants in total, including three independently

associated variants in 5p15.33 locus). For each locus, a green circle represents the top *p* value from the discovery samples, a red diamond represents the *p* value combining the discovery and the replication data, a black square represents the *p* value combining our discovery data and Chinese samples in Dai et al.²⁴ (for three variants identified in a cross-ancestry analysis of East Asians and Europeans in Dai et al.²⁴, see Supplementary Table 3). In summary, 28 variants at 25 loci achieved genome-wide significance, including 16 previously reported variants and 12 novel variants.

were conducted. Initial stratified LD score regression³⁶ using GTEx data (Supplementary Fig. 4; Supplementary Data 3) indicated that LUAD heritability drawn from EA populations are enriched in lung tissue-specific genes and chromatin features compared to other tissues (aggregated rank test $P = 1.36 \times 10^{-2}$ and 7.7×10^{-3} , respectively; Supplementary Data 3). Accordingly, we performed eQTL analyses using the Taiwanese dataset of adjacent normal lung tissues from 115 never-

smoking lung cancer patients (LTCNS) (Methods; Supplementary data 4). We performed colocalization analyses of eQTL genes using eCAVIAR³⁷ and HyPrColoc³⁸. A notable finding was the colocalization of *FADS1* at 11q12.2 (rs174559, posterior probability = 0.91) (Fig. 2; Supplementary Data 5), particularly since rs174559 was in LD with a recently identified functional variant (rs174557) regulating allelic *FADS1* expression in liver cells³⁹. *FADS1* encodes fatty acid desaturase 1,

Table 3 | Conditional and joint analyses identified independently associated risk SNPs for lung adenocarcinoma at two existing loci in East Asians

Chr	BP	SNP	Gene	GWAS analysis ^a				Conditional analysis ^b		Joint analysis ^c	
				Eff/Ref	EA F	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
5	1280477	rs13167280	<i>TERT</i>	A/G	0.22	1.47(1.37,1.57)	6.99×10^{-30}	1.33(1.24,1.42)	8.36×10^{-17}	1.29(1.20,1.38)	4.07×10^{-13}
5	1286516	rs2736100		A/G	0.56	0.75(0.72,0.77)	7.92×10^{-58}			0.80(0.77,0.83)	9.83×10^{-32}
5	1290319	rs62332591		G/T	0.52	0.79(0.75,0.83)	3.53×10^{-23}	0.87(0.83,0.91)	2.95×10^{-9}	0.87(0.83,0.92)	3.21×10^{-8}
6	41483390	rs9367106	<i>FOXP4</i>	C/G	0.32	1.20(1.15,1.26)	1.06×10^{-14}			1.19(1.14,1.25)	2.39×10^{-13}
6	41483960	rs12664490		T/C	0.16	0.80(0.75,0.85)	5.52×10^{-12}	0.81(0.76,0.86)	1.34×10^{-10}	0.81(0.76,0.86)	1.24×10^{-10}

All *p* values are nominal and two-sided.

^aData from single-variant analysis in GWAS.

^bConditional analysis using GCTA, conditioning on the lead variant in each locus.

^cJoint analysis using GCTA including the lead variant and the significant variants in conditional analysis.




Fig. 2 | Colocalization of lung adenocarcinoma GWAS signal from the new locus on Chr11 with *FADS1* eQTL signal. Colocalization analysis was performed using HyPrColoc with summary statistics from Taiwanese lung eQTL data (for *FADS1* gene, **A**) and those of EA GWAS discovery set (**B**). LD R² (1000 Genomes, EA) of each SNP with the GWAS lead SNP, rs174559 (red circle), is color-coded as shown in the

top band. Colocalization posterior probability (PP) is shown next to the candidate SNP, rs174559. Note that the *p* value of rs174559 in GWAS was based on the discovery data and did not include the Japanese replication data. All eQTL *p* values were two-sided and not adjusted for multiple testing.

which is a key enzyme in the metabolism of polyunsaturated fatty acids and plays a key role in inflammatory diseases⁴⁰. Higher *FADS1* levels in the lung tissues were associated with LUAD risk, which is consistent with its role in increasing the proliferation and migration of laryngeal squamous cell carcinoma through activation of the Akt/mTOR pathway⁴¹. Among the known loci, colocalization identified *TP63* at 3q28 and *ACVR1B* at 12q13.13 (Supplementary Data 5).

We then performed a TWAS using LCTCNS eQTL dataset. TWAS identified *FADS1* as a susceptibility gene from the 11q12.2 locus (TWAS $P = 3.01 \times 10^{-6}$) validating the finding from the colocalization analysis. We further identified *ELF5* (TWAS $P = 1.89 \times 10^{-8}$) as a novel gene from a locus (at 11p13) not originally passing the genome-wide significance threshold based on a single-variant test in our EA discovery GWAS

(Supplementary data 6, Methods). For these two loci, we also performed TWAS conditional analysis to assess whether genetically predicted expression of these genes explain most of the GWAS signal. When GWAS signal was conditioned on predicted expression of *ELF5*, most of the signal disappeared, adding support for *ELF5* as the main susceptibility gene in this locus (Supplementary Fig. 5A). *ELF5* encodes E74-like factor 5, a key transcription factor of alveologenesis of mammary glands⁴². Lower levels of *ELF5* were associated with LUAD risk in the TWAS. Similarly, when GWAS signal was conditioned on predicted expression of *FADS1*, the strongest part of the signal disappeared (Supplementary Fig. 5B). We further performed TWAS analysis using GTEx lung eQTL dataset (v8, $n = 515$, ~85% Europeans) and identified five genes from four loci (Supplementary Data 6). While identification

of *ELF5* was common between two datasets, TWAS using GTEx data identified four unique genes from three known loci (*DCBLDI*, *MPZL3*, *JAML*, and *LINCO0674*). Notably, *FADS1* was identified only by ancestry-matched LCTCNS eQTL dataset even with a ~4 times smaller sample size.

An investigation of the local environment of susceptibility loci revealed further plausible candidate genes that could be pursued in laboratory follow-up. For instance, rs137884934 on 3q22.3 maps to *PIK3CB* encoding an isoform of p110 catalytic subunit of Class IA PI3K⁴³. Previous studies have shown that PI3K/Akt/mTOR signaling pathway plays an important role in the development and progression of non-small cell lung cancer⁴⁴. Moreover, rs764014 on 15q21.3 is located adjacent to *NEDD4*, which is a negative regulator of tumor suppressor PTEN⁴⁵, which encodes a lipid phosphatase which counteracts the growth promoting effect of PI3K pathway⁴⁶.

Multi-ancestry meta-analysis in East Asian and European populations

To identify variants shared by EA and EUR populations, we performed a fixed effect, multi-ancestry GWAS meta-analysis including data from samples in EA (11,753 cases and 30,562 controls) and samples from EUR populations (11,273 cases and 55,483 controls). We identified four additional loci (Supplementary Table 7) with similar effect sizes in the two populations: rs1130866 (2p11.2, OR = 1.08, $P = 1.56 \times 10^{-8}$), rs2320614 (4q32.2, OR = 1.08, $P = 6.51 \times 10^{-9}$), rs34638657 (16q23.3, OR = 1.09, $P = 2.19 \times 10^{-9}$) and rs638868 (18q12.1, OR = 1.08, $P = 3.6 \times 10^{-8}$). Regional association plots are shown in Supplementary Fig. 6. A multi-ancestry meta-analysis stratified by smoking status did not reveal loci specific to never-smokers or individuals with a history of smoking (sample size information in Supplementary Table 8).

Among the four loci, rs1130866 at 2p11.2 is a missense variant (Ile131Thr) of *SFTPB*, encoding surfactant protein B. Pulmonary surfactant lines the alveoli of lung to reduce the surface tension and is essential for lung function, and increasing circulating level of pro-SFTPB suggested increased lung cancer risk based on prediagnostic samples⁴⁷. Notably, two other novel variants, rs34638657 at 16q23.3 (*MPHOSPH6*)^{48,49} and rs2320614 at 4q32.2 (*NAFI*)⁵⁰, are on or near genes implicated in telomere biology. Together with other known or new loci (rs2736100 *TERT*, rs4268071 *POT1*, rs75031349 *RTEL1*^{51,52}, rs7902587 *OBFC1*⁵³, rs35446936 *TERC*) (Supplementary data 7), our findings further support the role of telomere biology in LUAD.

Mendelian randomization analysis of telomere length

We performed a Mendelian randomization (MR) analysis to investigate a potential causal relationship between telomere length and the risk of LUAD. The MR analysis was based on 46 independent variants identified in a recent multi-ancestry GWAS of telomere length in the TOPMed study⁵⁴, cumulatively accounting for 3.74% of telomere length variance (Methods). Since genetic effects on telomere length showed no evidence of heterogeneity across populations in the TOPMed study, we used the genetic effects estimated based on all populations in the TOPMed study. Our MR analysis was based on MR-PRESSO⁵⁵, a robust approach that estimates causal effects after removing variants detected with evidence of pleiotropic effects. Genetically predicted longer telomere length was significantly associated with increased risk of LUAD with similar ORs (per one standard deviation change in genetically increased telomere length) between the two populations: OR = 2.61 (95% CI = 2.08, 3.28, $P = 8.14 \times 10^{-10}$) in EA populations, OR = 2.67 (95% CI = 2.07, 3.43, $P = 7.14 \times 10^{-9}$) in EUR populations, consistent with previous MR reports^{56–58} as well as a study of white blood cell DNA telomere length and lung cancer risk in multiple prospective cohorts⁵⁹. MR analyses stratified by smoking status showed similar results between never-smokers and individuals with a history of smoking (Supplementary Table 9). We performed sensitivity analyses using genetic effects estimated based on Asian and European populations in

the TOPMed study separately and found similar results (Supplementary Table 9).

Comparing the genetics of LUAD in EA and EUR populations

We systematically compared the effect size in EA vs. EUR populations of 38 susceptibility variants for LUAD. These included 12 variants identified in the current study, 26 variants previously reported in EA^{10,11,13–15,31} and/or EUR^{16,19,20} populations, and results of multi-ancestry meta-analyses combining data from EA and EUR²⁴ populations (Supplementary Data 8). As expected, ten SNP associations that were independently identified in both populations and through multi-ancestry analysis were very similar (Fig. 3A, B, C). In contrast, out of the 20 SNP associations initially identified in EA populations, two had $MAF < 0.01$, 11 showed no evidence of association within EUR populations at $P < 0.05$ (Fig. 3D and Fig. 3E, Supplementary Data 8), and 11 associations were significantly different between the two populations with $FDR < 0.05$. Similar population differences were observed among never-smokers and individuals with a history of smoking (Supplementary Fig. 7). For variants with $MAF > 0.01$ in both populations, the lack of association in EUR populations did not seem to be driven by low MAF or lower statistical power, as $MAFs$ in both populations for most variants were similar and GWAS in both populations had adequate power to detect at least some evidence of association (Supplementary Data 9). Further, evaluation of gene region plots that spanned 500 kb for these loci within EUR populations showed no or very weak evidence of association for other variants in the region as well as the lead variants from the EA populations (Supplementary Fig. 8A–J), with one exception (Supplementary Fig. 8K). For 8 SNPs initially identified in EUR populations, there was evidence of association for 5 variants in EA populations (Fig. 3F, Supplementary Fig. 9) although all variants were attenuated in the EA compared to the EUR population and one variant had $MAF < 1\%$ in EA; moreover, two variants were significantly weaker (Supplementary Data 8, Supplementary Fig. 9). Similar patterns were observed among never-smokers and individuals with smoking history (Supplementary Fig. 7).

We used LDSC²⁷ to evaluate the heritability and genetic correlation between individuals with a history of smoking and never-smokers within each population and POPCORN⁶⁰ across populations. The genetic correlation was weaker between never-smokers in EA and EUR populations compared to individuals with a history of smoking (Supplementary Fig. 10) although power was limited given the relatively small sample sizes within each group (Supplementary Table 8). Larger sample sizes are needed to estimate these characteristics more precisely.

Polygenic risk score and gene-smoking interaction analysis

We investigated whether the polygenic risk score (PRS), which was based on the cumulative effect of 25 independent susceptibility loci for LUAD in EA (Supplementary Table 4), interacted with smoking status to influence the risk of LUAD, given previous evidence of gene-environment interaction^{61,62}. Since only summary statistics were available for some datasets (instead of individual genotype data), we developed a statistical method for testing the multiplicative smoking-PRS interaction using the summary statistics for the susceptibility variants (Methods). Compared to the middle quintile that represents the average risk in the general population, the top quintile had OR of 2.07 (95% CI = 1.99, 2.15) for never-smokers and 1.80 (95% CI = 1.70, 1.89) for individuals with a history of smoking ($P_{\text{interaction}} = 0.0058$, Fig. 4, Supplementary Fig. 11), providing statistical evidence that the association between PRS and LUAD risk was higher for never-smokers. Moreover, we tested for the presence of multiplicative interactions between smoking status and each individual susceptibility variant in the PRS and found five variants with stronger associations in never-smokers than in individuals with a history of smoking ($P < 0.05$) (Supplementary Table 2).




Fig. 3 | Comparing odds ratios (ORs) of lung adenocarcinoma susceptibility variants between East Asian (EA) and European (EUR) populations. Here, the effect allele was defined as the minor allele in EA. Each error bar represents the 95% confidence interval of the OR (the center). **A** Susceptibility variants previously discovered (at genome-wide significance) in both EA and EUR populations. **B** Variants previously identified by multiple-ancestry meta-analysis of Chinese and EUR populations; **C** Variants were identified by multiple-ancestry meta-analysis combining EA samples in our study and EUR samples in ILCCO. **D** Variants identified

only in EA populations. **E** Novel variants identified in the current study; **F** Variants identified only in EUR populations. Variants are labeled with *, **, *** and **** corresponding to $0.01 \leq p_{\text{het}} < 0.05$, $0.001 \leq p_{\text{het}} < 0.01$, $0.0001 \leq p_{\text{het}} < 0.001$ and $p_{\text{het}} < 0.0001$, respectively; here, p_{het} (t-statistic, two-sided) is the p value for testing the heterogeneity of effect sizes between EA and EUR populations. Sample sizes for EUR populations in all panels: 11,273 cases and 55,483 controls. Sample sizes for EA populations: 11,753 cases and 30,562 controls for (A, B, C, D, and F); 21,658 cases and 150,676 controls for (E).




Fig. 4 | A polygenic risk score (PRS) is more strongly associated with risk of lung adenocarcinoma in never-smokers than in individuals with a history of smoking ($P = 0.0058$). The PRS was defined based on 25 independent variants that achieved genome-wide significance in EA with weights derived from the meta-analysis of the current study (Supplementary Table 4). The odds ratios (ORs) and

the standard errors of the 12 novel variants were based on 21,658 cases and 150,676 controls. The ORs and the standard errors of the other 13 variants were based on 11,753 cases and 30,562 controls. The figure shows the ORs and their 95% confidence intervals comparing each quintile group to the middle quintile for individuals with a history of smoking (blue) and never-smokers (red).

Genetic architecture, performance of PRS and sample size requirements in EA populations

To further investigate the underlying genetic architecture of susceptibility (Methods) to LUAD⁶³ in EA populations, we performed a GENESIS²⁶ analysis based on the GWAS summary statistics for our larger never-smoker dataset. We estimated that ~2275 (s.e. = 1167) susceptibility variants are independently associated with LUAD, suggesting that LUAD is a highly polygenic disease and most of the susceptibility variants have very small effect sizes. Based on the estimated parameters, we investigated how the performance of a PRS, measured as the area under the receiver operating characteristic curve (AUC), depended on the sample size of the training GWAS (Fig. 5). The AUC is predicted to be 60.7% (95% CI = 56.6%, 64.8%) at the current sample size and will increase to 66.9% (95% CI = 62.5%, 71.3%) when the sample size increases to 70,000 cases with one control per case and 68.4%

(95% CI = 64.0%, 72.8%) with 1000,000 controls. Of note, even a small increase of AUC value for a PRS can help identify many more subjects at risk⁶⁴.

Discussion

We conducted the largest GWAS of LUAD in an EA population to date and identified 12 novel susceptibility variants achieving genome-wide significance. In addition, two variants identified from a previous multi-ancestry meta-analysis achieved genome-wide significance as well in EA alone after we combined the reported summary data with our independent data. In total, including the previously described genetic variants, 28 variants at 25 loci have reached genome-wide significance for LUAD in EA populations, representing major progress in elucidating the genetic basis of LUAD. Finally, a multi-ancestry meta-analysis identified four




Fig. 5 | The expected area under the receiver operating characteristic curve (AUC) of a polygenic risk score (PRS) built based on a GWAS of specified sample sizes for lung adenocarcinoma in never-smoking East Asians. For “1 million

controls”, the x-coordinate represents the number of cases, assuming the study has 1 million controls. For “Equal number of cases and controls”, the x-coordinate represents the numbers of cases, assuming the same number of cases and controls.

additional loci in the combined EA and EUR populations, with consistent effects in both.

Our eQTL colocalization and TWAS analyses using an ancestry-matched lung eQTL dataset (EA population) identified novel LUAD susceptibility genes including *FADS1* and *ELF5*. Importantly, *FADS1* is regulated by sterol-response element-binding proteins (SREBPs)⁶⁵, which govern lipid metabolism in alveolar type II (ATII) cells⁶⁶. *ELF5* is also expressed in tissues with glandular/secretory epithelial cells including salivary gland and lung^{67,68} and 3.2% of lung alveolar type II cells express *ELF5* in GTEx single-cell expression data. Identification of *FADS1* and *ELF5* in our study suggests a role for alveolar lineage-specific genes and pathways in LUAD susceptibility. Notably, the missense variant (Ile131Thr), rs1130866, in *SFTPB* identified through the multi-ancestry analysis was a protein quantitative trait locus (pQTL) for *SFTPB* in blood⁶⁹, where the LUAD risk-associated A allele (Ile131) is correlated with increased *SFTPB* levels. Importantly, the genomic region encompassing rs1130866 presents weak LD and high SNP density, consistent with the presence of a recombination hot spot⁷⁰, and therefore fine-mapping inspecting low-frequency variants in the region is warranted. Our TWAS analyses using both ancestry-matched and ancestry-discordant lung eQTL datasets identified both common and unique genes from each dataset, highlighting potential benefits of an eQTL dataset of larger sample size and the importance of an ancestry-matched eQTL dataset, even at a smaller sample size, in detecting susceptibility genes.

We evaluated the presence of a gene-environment interaction with tobacco smoking in our EA data. We found that the association between a PRS (constructed by the lead variants at the 25 loci with genome-wide significance in EA) and LUAD in never-smokers was statistically significantly stronger than in individuals with a history of smoking (Fig. 4). This finding, together with our recent paper showing a stronger association of PRS for LUAD risk in non-coal users than in coal users⁷¹, provides evidence that genetic susceptibility may vary by exposure patterns in EA populations.

We systematically compared top GWAS findings that had been initially reported in one or the other or both populations. After accounting for differences in MAFs and statistical power as well as the local LD pattern of each locus (500 kb each side of the lead variant), we found that a substantial number of the associations initially reported in EA populations showed no signal in EUR populations. It might reflect causal variants for these loci not being tagged well in the EUR

populations. This might also suggest important differences between EA and EUR in the genetic architecture of LUAD samples, which could be caused by differential environmental exposures. Finally, this observation is also consistent with distinct tumor molecular characteristics (e.g., *EGFR* mutation prevalence was higher in Asians than EUR populations) observed in LUAD suggesting different etiologies influenced by genetic and/or environmental factors^{13,72,73}.

Our genetic architecture analysis suggested that LUAD is a highly polygenic disease. Expanding GWAS of LUAD will continue to identify many risk variants albeit with smaller effect sizes. Moreover, our analysis predicts that the AUC of PRS for EA never-smokers could be improved to 66.9% for a GWAS training dataset with 70,000 cases and 70,000 controls that could be further increased with a greater number of controls. Thus, an expanded GWAS in the future can lead to the substantial improvement in knowledge about the underlying genetic architecture of LUAD; increased understanding of how known or suspected lung cancer environmental risk factors interact with genetic susceptibility; and assessment of the potential clinical utility of risk models integrating both genetic and non-genetic risk factors^{74,75}.

There are several limitations in the current study. First, the discovery phase included subjects of diverse EA populations (Mainland China 38.2%, Japan 45.9%) and the replication phase only included subjects from Japan. However, our data did not show evidence of heterogeneity in effect sizes for susceptibility variants between Han Chinese and Japanese populations or across geographic locations (Supplementary Table 5), suggesting a minimal impact for using a single EA population for replication. Second, we were underpowered to conduct formal heritability correlation analyses to compare the genetic architecture in EA and EUR populations stratified by smoking status; larger studies will be needed to conclusively characterize differences. Furthermore, completely elucidating the genetic basis of ancestry differences requires detailed information about age of onset, family history and exposures. Finally, rs4268071 (Table 2) achieved genome-wide significance in the discovery data but replication data were not available. While the significance was primarily driven by Japanese samples (MAF = 0.04 in Japanese and <1% in other populations), there was no evidence of heterogeneity in effect estimates across EA populations. Replication is warranted to further establish its etiological role.

In conclusion, we identified 12 novel variants in a GWAS of LUAD in EA populations as well as 4 novel variants in a multi-ancestry meta-

analysis of EA and EUR populations. Colocalization and TWAS analyses using an ancestry-matched lung tissue eQTL dataset identified candidate susceptibility genes with suggested roles in alveolar lineage. At the same time, a large majority of variants identified in the EA GWAS showed no evidence of association in EUR populations. Larger samples sizes with data on environmental risk factors will be needed to further characterize the etiologic differences between these populations. Finally, our genetic architecture analysis suggests that the performance and the clinical utility of the PRS will be substantially improved by larger GWAS in the future.

Methods

Ethics statement

All participants provided informed consent according to protocols that were evaluated and approved by the internal review boards of the contributing centers. Protocols used to generate new, unpublished data presented in this paper were approved by the National Cancer Center Institutional Review Board, Japan and the Aichi Cancer Center Ethics Committee, Japan.

Overview of study

We conducted a two-phase GWAS meta-analysis of LUAD in EA populations, including Female Lung Cancer Consortium in Asia (FLCCA), Nanjing Lung Cancer Study (NJLCS)^{10,24}, National Cancer Center of Japan (NCC) Research Institute and Aichi Cancer Center (ACC). For the FLCCA study, details of the study design, participating studies, case ascertainment, genotyping, and quality controls have been described in detail⁹. Briefly, this international consortium is composed of Asian women who never smoked and resided in Mainland China, Hong Kong, Singapore, Taiwan, South Korea and Japan at the time of recruitment. All were genotyped using the Illumina 660W, 370K and 610Q microarrays.

The NCC study included lung cancer patients from NCC and BioBank Japan (BBJ) and non-cancer controls from the Japan Public Health Center-based Prospective Study and the Japan Multi-Institutional Collaborative Cohort Study, genotyped by Illumina HumanOmniExpress and HumanOmni-Quad genotyping platforms. The ACC study included lung cancer patients from the Aichi Cancer Center, Kyoto University, Okayama University and Hyogo College of Medicine and non-cancer controls from the Nagahama Study and the Aichi Cancer center. Samples were genotyped by Illumina 610k and Illumina660k platforms^{15,76}. The NJLCS study at the Nanjing Medical University was based on meta-analysis of three studies: the Nanjing GWAS with subjects from Nanjing and Shanghai, the Beijing study with subjects from Beijing and Wuhan (genotyped by Affymetrix Genome-Wide Human SNP Array 6.0) and the Oncoarray GWAS^{10,77,78}.

The replication study included cases from multiple sources (BBJ, NCC, Kanagawa Cancer Center, Akita University Hospital, Tokyo Medical and Dental University, Hospital and Gunma University Hospital, and Fukushima Medical University School of Medicine) and non-cancer controls from BioBank Japan. Cases were genotyped using the Invader assay and the control samples in BioBank Japan were genotyped using the Illumina HumanOmniExpress genotyping platform.

For the multi-ancestry meta-analyses of LUAD and cross-population comparison of top GWAS findings with both never-smokers and individuals with a history of smoking, we used 11,273 cases and 55,483 controls of European ancestry in the Integrative Analysis of Lung Cancer Etiology and Risk team of the International Lung Cancer Consortium (INTEGRAL-ILCCO)¹⁶ (Supplementary Table 8). For the multi-ancestry analysis and cross-population comparisons of smokers, we used European samples genotyped with the OncoArray platform in the ILCCO study (Supplementary Table 8). For the multi-ancestry and cross-population comparisons analysis of never-smokers, we used the GWAS of European never-smoking subjects from Hung et al.²¹.

Quality control, imputation and association analysis in EA populations

For each study, SNPs with minor allele frequency (MAF) < 0.01, Hardy-Weinberg Equilibrium (HWE) p value < 10^{-6} in controls were removed; subjects with missing rate >3%, sex discrepancy, or displaying non-East Asian ancestry based on principal component analysis scores were removed. Moreover, for any pairs of subjects estimated to be related with identity by descent $\text{pihat} > 0.10$ using PLINK (V2.0), we removed one subject. Imputation was performed using IMPUTE2 and the 1000 Genomes Project East Asian samples (Phase 3) as reference. After imputation, SNPs with imputation quality score ≥ 0.5 were used for association analysis in each study. Logistic regression under an additive model was performed using SNPTest (V2) or PLINK2 based on imputed genotypic dosage data adjusting for smoking (if both smokers and never smokers were present) and PCA scores to control for population stratification. Meta-analysis was performed using inverse-variance weighted fixed effects methods. All p values were two-sided. We consider the following variants as novel for the GWAS in EA: (1) the lead variant with $p < 5 \times 10^{-8}$ in a locus that has not been previously reported in either EA or EUR populations, or (2) a secondary variant with $p < 5 \times 10^{-8}$ conditioning on the lead variant in a previously reported locus in either EA or EUR populations with the requirement that the LD $R^2 \leq 0.2$ between the secondary and the lead variants in both populations.

LDSC²⁷ was used to estimate the heritability attributed to genome-wide common variants and to assess the potential inflation due to insufficient correction of population stratification. LDSC was also used to estimate the genetic correlation of LUAD between never-smokers and individuals with a history of smoking in each population. We used POPCORN⁶⁰ to estimate the genetic correlation between EA and EUR populations because LD patterns are expected to be different. To account for the difference of allele frequencies in the two populations, we also used POPCORN to estimate the cross-population genetic-impact correlation that was defined as the correlation of population specific phenotypic variance explained by each SNP.

Conditional analysis and fine mapping

To identify independently associated SNPs at an established susceptibility locus, we performed conditional analysis using software Genome-wide Complex Trait Analysis (GCTA)⁷⁹ based on the GWAS meta-analysis summary results of EA populations. LD for the conditional analysis was calculated using a reference population of 4544 controls from the FLCCA study to achieve a desirable accuracy. Here, genotypes for FLCCA were imputed using IMPUTE2 and the 1000 Genomes Project (Phase 3) reference samples with EA ancestry. SNPs with imputation quality < 0.5 were excluded from the reference set for conditional analysis. Conditional analysis was restricted to 14 loci with lead SNPs achieving genome-wide significance in the discovery-phase meta-analysis. We did not perform conditional analyses for other new SNPs that did not achieve genome-wide significance in the discovery-phase meta-analysis because secondary SNPs would not survive multiple testing correction. Conditional analysis was restricted to SNPs less than 500 kb from the lead SNP of each locus. To identify multiple potentially independent SNPs in one locus, we performed stepwise conditional analysis using GCTA. All SNPs identified with $P < 5 \times 10^{-8}$ and the lead SNP of the locus were put into one model to derive the joint estimate of ORs, appropriately adjusting for LD among all SNPs. Only SNPs with p value < 5×10^{-8} in both conditional and joint analyses were considered to be independently associated SNPs.

For 11 out of the 14 loci with genome-wide significance in the discovery phase, we performed a Bayesian fine-mapping analysis using FINEMAP³² to nominate 95% credible set variants using the same set of imputed genotypes of 4544 FLCCA control subjects as an LD reference. We did not perform fine-mapping analysis for two loci in MHC regions, because of the complex and extensive LD patterns in this region. We

also excluded the locus at 7q31 because the lead SNP, rs4268071, had MAF < 1% in our LD reference population. MAF of this variant is 4% in the Japanese populations (45.8% of cases and 74.5% of controls in the discovery set) but < 1% in other EA populations included in our study. For FINEMAP analysis, we tested the variants within ± 500 kb of the lead SNP and set the number of maximum causal variants as the number of independent signals ($P \leq 10^{-5}$) observed in the conditional analysis for each locus.

Proportion of familial risk explained

We considered a set of identified variants for LUAD. For SNP t , we defined p_t as the frequency of the risk allele and OR_t as the estimated per-allele odds ratio. Under a multiplicative model, the fraction of the familial risk explained by the set of SNPs was calculated as $\sum_t \log(\lambda_t) / \log(\lambda_0)$, where λ_0 is the observed familial risk to the first degree of LUAD cases and λ_t is the familial risk due to the t^{th} SNP:

$$\lambda_t = \frac{p_t OR_t^2 + (1 - p_t)}{(p_t OR_t + 1 - p_t)^2}. \quad (1)$$

Heritability partitioning in functional classes and tissue-specific analyses

Stratified LD score regression (sLDSC)⁸⁰ was conducted to identify functional annotations enriched for LUAD heritability using summary statistics from the discovery phase of meta-analysis in EA populations. In addition to the functional annotations provided by the sLDSC package, we also analyzed the gene sets defined by smoking studies: differentially expressed genes in peripheral blood mononuclear cells upon nicotine treatment (“PBMC nicotine” gene set) from Moyerbrailean et al.⁸¹, those in non-tumorous lungs between current- and never-smokers (“Lung smoking” gene set) from Bosse et al.⁸², and those in normal bronchial airway epithelial cells between current- and never-smokers (“Airway smoking” gene set) from Beane et al.⁸³. An annotation was considered to be significantly enriched for LUAD heritability if FDR < 0.05.

We then performed sLDSC to prioritize relevant tissue types (lung, blood/immune, and brain/CNS) using tissue-specific expressed genes from GTEx v6p (53 tissue types) and other public expression datasets (152 tissue types), as well as tissue-specific chromatin annotations from EnTEX (111 annotations in 26 tissue types) and Roadmap dataset (378 annotations in 85 tissue types) as described by Finucane and colleagues³⁶. We used GTEx v6p expression data based on a comparison with v8 data, where a median of 83% of tissue-specific differentially expressed genes were shared between two versions. In general, we did not find significant enrichment for individual annotations after adjusting for the multiple testing. To increase the power of prioritizing relevant tissues (lung, blood/immune, and brain/CNS), we performed an aggregated analysis to test if p values from one tissue (e.g., lung) tended to be smaller than those from the other two tissue groups (blood/immune, and brain/CNS) using the Wilcoxon rank test.

eQTL colocalization analysis and TWAS

EA lung eQTL dataset is based on a cohort of 115 never-smoking LUAD patients from Taiwan, referred to as LCTCNS (Lung cancer tissue cohort of never-smokers). Expression array data was obtained for non-tumor lung tissues of these patients using the Illumina WG-DASL HumanRef-8 v3 or HumanHT-12 v4 BeadChip (Illumina Inc.) (Gene Expression Omnibus accession number GSE46539)⁸⁴. Genotype data from buffy coat DNA was obtained using the Illumina Human660W-Quad BeadChip. A systematic quality control for the genotype data was performed as previously described¹² (SNPs were excluded if call rate < 90%, MAF < 5%, or $P < 0.0001$ based on the Hardy-Weinberg equilibrium test. Samples were excluded if call rate < 90%, sex discrepancies based on the X chromosome heterozygosity, contaminated samples

with high heterozygosity scores, or first or second-degree relatives), and imputation was carried out using Minimac4 (V4.0.3) with the 1000 Genomes reference set (all populations). For eQTL analysis, expression data was processed for background correction as previously described⁸⁴. Briefly, we kept the probes that are present in both the BeadChip platforms and further removed those with low expression levels (detection $p > 0.05$). Based on the data at the remaining 24,216 probes, we applied model-based background correction. Log₂-transformed expression levels of 24,216 probes were then used to obtain 20 latent factors based on probabilistic estimation of expression residuals (PEER) while specifying batch, sex, age, medical operation status, RNA integrity number, and RNA input quantity as known confounders. The expression residuals from PEER were then inverse rank transformed to the standard normal distribution (the inverse rank transformed residuals) and were used as the dependent variable in the expression levels for eQTL analysis. eQTL analysis was conducted for 29 GWAS lead SNPs (all EA loci including discovery, replication, and conditional signals plus new loci from the multi-ancestry GWAS). In LCTCNS, all these SNPs have a MAF of > 0.01. For each GWAS lead SNP, its association with each probe located within ± 500 kb of the SNP was tested using an additive linear model where the dependent variable was the expression level as described above and the independent variable was the effect allele count. Based on the resulting p values of these eQTL analyses for all 29 SNPs, the corresponding Benjamini–Hochberg FDR was calculated. Colocalization analysis was performed using eCAVIAR³⁷ and HyPrColoc³⁸ via ezQTL platform for eight GWAS lead SNP-eQTL gene pairs displaying FDR < 0.05 in LCTCNS (Supplementary Data 5). For each of these eight SNP-probe pairs, we further examined the association between the probe and SNPs within ± 100 kb of the lead SNP using Matrix eQTL to obtain the summary statistics as an input to ezQTL for colocalization analysis using HyPrColoc and eCAVIAR. For loci on MHC regions, ± 10 kb window was used for computational efficiency of colocalization analyses. LD matrix was obtained from 1000 Genomes EA populations. For HyPrColoc, posterior probability of > 0.7 was used as a cutoff for colocalization. For eCAVIAR analysis, colocalization posterior probability (CLPP) score > 0.01 was used as a cutoff for colocalization.

For TWAS, we adopted FUSION⁸⁵ using LCTCNS or GTEx v8 lung eQTL data and summary statistics of EA discovery GWAS meta-analysis. We computed weights using the elastic-net regression model for 24,216 expression probes (LCTCNS) or 24,687 genes (GTEx v8 lung) and *cis*-SNPs within 500 kb of the gene for each probe. LD matrix was obtained from 1000 Genomes EA populations. We performed association analysis for 1875 expression probes (LCTCNS) or 5534 genes (GTEx v8 lung) with cross-validation cutoff of $R^2 > 0.05$ based on the elastic-net model. We defined a significant transcriptome-wide association as TWAS $P < 2.6 \times 10^{-5}$ (0.05/1875; LCTCNS) or $P < 9 \times 10^{-6}$ (0.05/5534; GTEx v8 lung) based on Bonferroni correction. For two loci passing this cutoff from LCTCNS analysis (*ELF5* and *FADS1*), we further performed conditional analysis as implemented in FUSION by conditioning the GWAS signal on the predicted expression of the probe with the best TWAS P value.

Mendelian randomization

We performed MR analysis to investigate the potential causal relationship between telomere length and the risk of LUAD. MR analysis was based on 46 common SNPs identified in a recent multi-ancestry meta-analysis of telomere length in the TOPMed⁵⁴ study. The original paper identified 48 variants associated with telomere length that collectively explained 4.35% of telomere length variance; two of them at the *TERT* locus were excluded using the LD filter $R^2 < 0.05$ that together explained 0.61% of the telomere length variance; the remaining 46 variants included in our MR analysis explained 3.74% of telomere length variance. Because there was no significant heterogeneity of effect sizes on telomere length across populations (Table S4 in

Taub et al.⁵⁴), the primary MR analyses were based on the estimated effect sizes combining all samples in the TOPMed study in a joint regression model for telomere length. Analyses were based on MR-PRESSO⁸⁶, a powerful and robust approach designed to deal with widespread horizontal pleiotropy. This approach uses a formal testing framework to (1) detect the presence of horizontal pleiotropy, (2) detect variant outliers, (3) evaluate distortion, and (4) re-estimate causal effect sizes after removing potentially problematic variants. According to simulations, this approach is best suited when horizontal pleiotropy occurs in <50% of instruments. This approach identified 5–7 outlier variants in our data. The estimated β from MR analysis was converted as OR, interpreted as risk increase per standard deviation (640 base pairs⁸⁷) increase of the genetically predicted telomere length.

Testing the interaction between polygenic risk score and smoking status

We investigated whether the PRS, which was calculated based on 25 independent SNPs associated with LUAD in EA populations (Supplementary Table 4, excluding three variants identified by conditional analysis), interacted with smoking status for LUAD risk. Because we have only GWAS summary statistics instead of individual-level data for smokers and never-smokers, we developed a statistical method for testing the interaction using summary statistics separately from smokers and never-smokers. Suppose that we have n^{1+} smoking cases, n^{0+} never-smoking cases, n^{1-} smoking controls and n^{0-} never-smoking controls. Let x_{it}^{s+} and x_{jt}^{s-} be the genotype of SNP t for the i^{th} case and the j^{th} control, where $s=1$ indicates smokers and 0 indicates never-smokers. Given smoking status s , we define $PRS_i^{s+} = \sum_{t=1}^T \beta_t x_{it}^{s+}$ and $PRS_j^{s-} = \sum_{t=1}^T \beta_t x_{jt}^{s-}$ as the PRS for cases and controls, respectively. For smokers ($s=1$), the association between PRS and disease risk can be quantified as:

$$\Delta_1 = \frac{1}{n^{1+}} \sum_{i=1}^{n^{1+}} PRS_i^{1+} - \frac{1}{n^{1-}} \sum_{j=1}^{n^{1-}} PRS_j^{1-}, \tag{2}$$

the difference of average PRS between cases and controls. Similarly, we define Δ_0 to be the difference of average PRS between cases and controls for never-smokers. Testing the PRS*smoking interaction can be done using $Z = \frac{\Delta_1 - \Delta_0}{\sqrt{\text{var}(\Delta_1^2) + \text{var}(\Delta_0^2)}}$. Under the null hypothesis of no interaction for all variants, $Z \sim N(0,1)$ asymptotically. Assuming SNPs are independent, we derive $Z = \sum_{t=1}^T (w_t^1 z_t^1 - w_t^0 z_t^0)$, where z_t^s is the z-score for testing association for SNP t in subjects with smoking status s . The weight is given as

$$w_t^s = \frac{\beta_t \sqrt{\frac{(\sigma_t^{s+})^2}{n^{s+}} + \frac{(\sigma_t^{s-})^2}{n^{s-}}}}{\sqrt{\sum_{t=1}^T \beta_t^2 \left(\frac{(\sigma_t^{1+})^2}{n^{1+}} + \frac{(\sigma_t^{1-})^2}{n^{1-}} + \frac{(\sigma_t^{0+})^2}{n^{0+}} + \frac{(\sigma_t^{0-})^2}{n^{0-}} \right)}}. \tag{3}$$

Here, $(\sigma_t^{s+})^2$ and $(\sigma_t^{s-})^2$ are the genotypic variances for SNP t in cases and controls, respectively.

We note that both discovery and replication data are included for testing PRS smoking interaction novel variants included in our PRS to maximize the power of statistical testing. In particular, only the discovery data were available and included for previously identified variants; both discovery and replication data were included for new variants to increase the statistical power. To do this, w_t^s was modified to have SNP-specific sample sizes. All analyses were done using R (x64 4.1.0).

GENESIS analysis for projecting yield of future expanded studies

The genetic architecture of a disease is defined as the number of susceptibility SNPs and the distribution of their effect sizes²⁶. When these

parameters are estimated, one can estimate the number of variants achieving genome-wide significance and the accuracy of a polygenic risk model trained using a GWAS with a given sample size. In the current study, we estimated the genetic architecture using GENESIS (GENetic Estimation and Inference in Structured samples)²⁶ based on the GWAS summary statistics with LD scores calculated based on the genotypes of the subjects of EA ancestry in the 1000 Genomes Project. Since GENESIS requires a large sample size to derive reliable estimates, we performed analysis only for never-smokers in EA. The three-component model $\beta_m \sim \pi p_1 N(0, \sigma_1^2) + \pi p_2 N(0, \sigma_2^2) + (1 - \pi) \delta_0$ best fit the never-smoker data in EA, where β_m represents effects sizes, π denotes the fraction of truly associated variants in the genome, δ_0 denotes the point mass at zero, σ_i^2 denotes the variance of effect sizes for the i^{th} component, πp_i ($i=1,2$) represents the fraction of variants with effect size following $N(0, \sigma_i^2)$. Based on this estimated genetic architecture, we calculated the expected number of variants reaching genome-wide significance for a given GWAS and calculated the expected area under the receiver operating characteristic curve (AUC) for an additive polygenic risk prediction model built based on a discovery GWAS for a given sample size. The uncertainty of the AUC was induced by the uncertainty in the estimated parameters in GENESIS ($\Gamma = (\pi, p_1, p_2, \sigma_1^2, \sigma_2^2)$) because of the limited sample size in our summary data. We used a resampling approach to estimate the standard error of AUC. Briefly, we randomly simulated 1000 sets of parameters Γ^k given the estimated $\bar{\Gamma}$ and the estimated covariance matrix, and calculated AUC_k for each simulated parameter Γ^k for a given sample size. The standard error was calculated based on the 1000 sets of AUC values.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data supporting the findings described in this paper are available in the paper and in the Supplementary Information and from the corresponding author or as otherwise indicated upon request. Full TWAS results are included in Supplementary Data 6. The summary statistics for the meta-analysis of the 4 GWAS datasets in East Asian populations for SNPs with $p \leq 0.01$ are in Supplementary Data 10. The results of the replication study for the 38 SNPs tested and the meta-analysis with the GWAS data are in Supplementary Data 11. For the FLCCA study, the GWAS summary data for SNPs with $p < 0.01$ in the study and all SNPs with genome-wide significance in the meta-analysis of East Asian samples are in Supplementary Data 12. The individual genotype data for the FLCCA data are in dbGaP phs000716.v1.p1 (Genome-Wide Association Study of Lung Cancer Susceptibility in Never-Smoking Women in Asia). For the NJLCS study, the GWAS summary data for SNPs with $p < 0.01$ in the study and all SNPs with genome-wide significance in the meta-analysis of East Asian samples are in Supplementary Data 13. For the NCC and ACC studies, please contact Kouya Shiraiishi at kshirais@ncc.go.jp or Takashi Kohno at tkkohno@ncc.go.jp for summary statistics. The GWAS data for the European populations contributing to this study are available at dbGap under accession phs000877.v1.p1 (Transdisciplinary Research Into Cancer of the Lung (TRICL), https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000876.v2.p1), phs001273.v3.p2 (Oncoarray Consortium, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001273.v3.p2). To gain access to all data in dbGaP cited in this paper, please apply for dbGaP Authorized Access. The expression data of the lung cancer tissue cohort of never-smokers in Taiwan are publicly available at Gene Expression Omnibus under accession number GSE46539. The expression and eQTL data from GTEx (v6 and v8) are available from <https://gtexportal.org/home/datasets>.

References

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **68**, 394–424 (2018).
2. Cheng, T. Y. et al. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. *J. Thorac. Oncol.* **11**, 1653–1671 (2016).
3. Barta, J. A., Powell, C. A. & Wisnivesky, J. P. Global Epidemiology of Lung Cancer. *Ann. Glob. Health* **85**, 8 (2019).
4. Cao, M. & Chen, W. Epidemiology of lung cancer in China. *Thorac. Cancer* **10**, 3–7 (2019).
5. Kinoshita, F. L., Ito, Y. & Nakayama, T. Trends in Lung Cancer Incidence Rates by Histological Type in 1975–2008: A Population-Based Study in Osaka, Japan. *J. Epidemiol.* **26**, 579–586 (2016).
6. Landi, M. T. et al. Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers. *Am. J. Epidemiol.* **190**, 962–976 (2021).
7. Sisti, J. & Boffetta, P. What proportion of lung cancer in never-smokers can be attributed to known risk factors? *Int J. Cancer* **131**, 265–275 (2012).
8. Schottenfeld D., Fraumeni J.F. *Cancer epidemiology and prevention*, 3rd edn. (Oxford University Press, 2006).
9. Lan, Q. et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nat. Genet.* **44**, 1330–1335 (2012).
10. Hu, Z. et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. *Nat. Genet.* **43**, 792–796 (2011).
11. Wang, Z. et al. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. *Hum. Mol. Genet.* **25**, 620–629 (2016).
12. Hsiung, C. A. et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. *PLoS Genet.* **6**, e1001051 (2010).
13. Seow, W. J. et al. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. *Hum. Mol. Genet.* **26**, 454–465 (2017).
14. Miki, D. et al. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. *Nat. Genet.* **42**, 893–896 (2010).
15. Shiraishi, K. et al. A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. *Nat. Genet.* **44**, 900–903 (2012).
16. McKay, J. D. et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat. Genet.* **49**, 1126–1132 (2017).
17. Wang, Y. et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. *Nat. Genet.* **46**, 736–741 (2014).
18. Landi, M. T. et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *Am. J. Hum. Genet.* **85**, 679–691 (2009).
19. Amos, C. I. et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat. Genet.* **40**, 616–622 (2008).
20. Wang, Y. et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. *Nat. Genet.* **40**, 1407–1409 (2008).
21. Hung, R. J. et al. Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1L1 Region. *J. Thorac. Oncol.* **14**, 1360–1369 (2019).
22. Hung, R. J. et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* **452**, 633–637 (2008).
23. Wu, C. et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. *Cancer Res.* **69**, 5065–5072 (2009).
24. Dai, J. et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. *Lancet Respir. Med.* **7**, 881–891 (2019).
25. Byun, J. et al. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. *Nat. Genet.* **54**, 1167–1177 (2022).
26. Zhang, Y., Qi, G., Park, J. H. & Chatterjee, N. Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. *Nat. Genet.* **50**, 1318–1326 (2018).
27. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
28. Dong, J. et al. Fine mapping of chromosome 5p15.33 identifies novel lung cancer susceptibility loci in Han Chinese. *Int J. Cancer* **141**, 447–456 (2017).
29. Matakidou, A., Eisen, T. & Houlston, R. S. Systematic review of the relationship between family history and lung cancer risk. *Br. J. Cancer* **93**, 825–833 (2005).
30. Nagai, A. et al. Overview of the BioBank Japan Project: Study design and profile. *J. Epidemiol.* **27**, S2–S8 (2017).
31. Timofeeva, M. N. et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. *Hum. Mol. Genet.* **21**, 4980–4995 (2012).
32. Benner, C. et al. FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
33. Boyle, A. P. et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790–1797 (2012).
34. Ward, L. D. & Kellis, M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Res.* **44**, D877–D881 (2016).
35. Breeze, C. E. et al. Integrative analysis of 3604 GWAS reveals multiple novel cell type-specific regulatory associations. *Genome Biol.* **23**, 13 (2022).
36. Finucane, H. K. et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
37. Hormozdiari, F. et al. Colocalization of GWAS and eQTL Signals Detects Target Genes. *Am. J. Hum. Genet.* **99**, 1245–1260 (2016).
38. Foley, C. N. et al. A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nat. Commun.* **12**, 764 (2021).
39. Pan, G. et al. PATZ1 down-regulates FADS1 by binding to rs174557 and is opposed by SP1/SREBP1c. *Nucleic Acids Res.* **45**, 2408–2422 (2017).
40. Glaser, C., Heinrich, J. & Koletzko, B. Role of FADS1 and FADS2 polymorphisms in polyunsaturated fatty acid metabolism. *Metabolism* **59**, 993–999 (2010).
41. Zhao, R. et al. FADS1 promotes the progression of laryngeal squamous cell carcinoma through activating AKT/mTOR signaling. *Cell Death Dis.* **11**, 272 (2020).
42. Oakes, S. R. et al. The Ets transcription factor E1f5 specifies mammary alveolar cell fate. *Genes Dev.* **22**, 581–586 (2008).
43. Tan, A. C. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). *Thorac. Cancer* **11**, 511–518 (2020).
44. Cheng, H. et al. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. *Lung Cancer Manag.* **3**, 67–75 (2014).
45. Amodio, N. et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. *Am. J. Pathol.* **177**, 2622–2634 (2010).

46. Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proc. Natl Acad. Sci. U. S. A* **96**, 4240–4245 (1999).
47. Sin, D. D. et al. Pro-surfactant protein B as a biomarker for lung cancer prediction. *J. Clin. Oncol.* **31**, 4536–4543 (2013).
48. Lehner, B. & Sanderson, C. M. A protein interaction framework for human mRNA degradation. *Genome Res.* **14**, 1315–1323 (2004).
49. Moon, D. H. et al. Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component. *Nat. Genet.* **47**, 1482–1488 (2015).
50. Stanley, S. E. et al. Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. *Sci. Transl. Med.* **8**, 351ra107 (2016).
51. Vannier, J. B., Pavicic-Kaltenbrunner, V., Petalcorin, M. I., Ding, H. & Boulton, S. J. RTEL1 dismantles T loops and counteracts telomeric G4-DNA to maintain telomere integrity. *Cell* **149**, 795–806 (2012).
52. Sarek, G., Vannier, J. B., Panier, S., Petrini, J. H. J. & Boulton, S. J. TRF2 recruits RTEL1 to telomeres in S phase to promote t-loop unwinding. *Mol. Cell* **57**, 622–635 (2015).
53. Miyake, Y. et al. RPA-like mammalian Ctc1-Stn1-Ten1 complex binds to single-stranded DNA and protects telomeres independently of the Pot1 pathway. *Mol. Cell* **36**, 193–206 (2009).
54. Margaret, A. T. et al. Novel genetic determinants of telomere length from a trans-ethnic analysis of 109,122 whole genome sequences in TOPMed. *Cell Genom.* **2**, 100084 (2022).
55. Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Publisher Correction: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* **50**, 1196 (2018).
56. Machiela, M. J. et al. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. *Int J. Cancer* **137**, 311–319 (2015).
57. Telomeres Mendelian Randomization, C. et al. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. *JAMA Oncol.* **3**, 636–651 (2017).
58. Zhang, C. et al. Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. *Hum. Mol. Genet.* **24**, 5356–5366 (2015).
59. Seow, W. J. et al. Telomere length in white blood cell DNA and lung cancer: a pooled analysis of three prospective cohorts. *Cancer Res.* **74**, 4090–4098 (2014).
60. Brown BC, Asian Genetic Epidemiology Network Type 2 Diabetes C, Ye CJ, Price AL, Zaitlen N. Transethnic Genetic-Correlation Estimates from Summary Statistics. *Am. J. Hum. Genet.* **99**, 76–88 (2016).
61. Zhang, R. et al. A genome-wide gene-environment interaction analysis for tobacco smoke and lung cancer susceptibility. *Carcinogenesis* **35**, 1528–1535 (2014).
62. Li, Y. et al. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. *Carcinogenesis* **39**, 336–346 (2018).
63. Zhang, Y. D. et al. Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nat. Commun.* **11**, 3353 (2020).
64. Maas, P. et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. *JAMA Oncol.* **2**, 1295–1302 (2016).
65. Angelidis, I. et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. *Nat. Commun.* **10**, 963 (2019).
66. Plantier, L. et al. Activation of sterol-response element-binding proteins (SREBP) in alveolar type II cells enhances lipogenesis causing pulmonary lipotoxicity. *J. Biol. Chem.* **287**, 10099–10114 (2012).
67. Choi, Y. S., Chakrabarti, R., Escamilla-Hernandez, R. & Sinha, S. Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. *Dev. Biol.* **329**, 227–241 (2009).
68. Chakrabarti, R. et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nat. Cell Biol.* **14**, 1212–1222 (2012).
69. Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. *Science* **361**, 769–773 (2018).
70. Hamvas, A. et al. Comprehensive genetic variant discovery in the surfactant protein B gene. *Pediatr. Res.* **62**, 170–175 (2007).
71. Blechter, B. et al. Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia. *Environ. Int* **147**, 105975 (2021).
72. Chen, J. et al. Genomic landscape of lung adenocarcinoma in East Asians. *Nat. Genet.* **52**, 177–186 (2020).
73. Carrot-Zhang, J. et al. Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. *Cancer Disco.* **11**, 591–598 (2021).
74. Katki, H. A., Kovalchik, S. A., Berg, C. D., Cheung, L. C. & Chaturvedi, A. K. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. *JAMA* **315**, 2300–2311 (2016).
75. Chien, L. H. et al. Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. *Cancer Epidemiol. Biomark. Prev.* **29**, 452–459 (2020).
76. Shiraishi, K. et al. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. *Nat. Commun.* **7**, 12451 (2016).
77. Dong, J. et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. *Nat. Genet.* **44**, 895–899 (2012).
78. Wang, L. et al. Genetically determined height was associated with lung cancer risk in East Asian population. *Cancer Med.* **7**, 3445–3452 (2018).
79. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–375 (2012).
80. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
81. Moyerbrailean, G. A. et al. High-throughput allele-specific expression across 250 environmental conditions. *Genome Res.* **26**, 1627–1638 (2016).
82. Bosse, Y. et al. Molecular signature of smoking in human lung tissues. *Cancer Res.* **72**, 3753–3763 (2012).
83. Beane, J. et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. *Cancer Prev. Res. (Philo.)* **4**, 803–817 (2011).
84. Chang, I. S. et al. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. *Am. J. Respir. Crit. Care Med.* **195**, 663–673 (2017).
85. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nat. Genet.* **48**, 245–252 (2016).
86. Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).

87. Mangino, M. et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. *Hum. Mol. Genet.* **21**, 5385–5394 (2012).

Acknowledgements

This work utilized the computational resources of the NIH HPC Biowulf cluster. (<http://hpc.nih.gov>).

Female Lung Cancer Consortium in Asia (NCI): This study was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, Culture and Technology of Japan, a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry Health, Labor and Welfare of Japan, by Health and Labor Sciences Research Grants for Research on Applying Health Technology from the Ministry of Health, Labor and Welfare of Japan, by the National Cancer Center Research and Development Fund, the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (grant No. 2011-0016106), a grant of the National Project for Personalized Genomic Medicine, Ministry for Health & Welfare, Republic of Korea (A11218-11-GMO4), the Program for Changjiang Scholars and Innovative Research Team in University in China (IRT_14R40 to K.C.), the National Science & Technology Pillar Program (2011BAI09B00), MOE 111 Project (B13016), the National Natural Science Foundation of China (No. 30772531, and 81272618), Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (No. 2012A061400006), Special Fund for Research in the Public Interest from the National Health and Family Planning Commission of PRC (No. 201402031), and the Ministry of Science and Technology, Taiwan (MOST 103-2325-B-400-023 & 104-2325-B-400-012). The Japan Lung Cancer Study (JLCS) was supported in part by the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development (15ck0106096h0002) and the Management Expenses Grants from the Government to the National Cancer Center (26-A-1) for Biobank. BioBank Japan was supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government. The Japan Public Health Center-based prospective Study (the JPHC Study) was supported by the National Cancer Center Research and Development Fund (23-A-31[toku], 26-A-2, 29-A-4, and 2020-J-4) (since 2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010). The Taiwan GELAC Study (Genetic Epidemiological Study for Lung AdenoCarcinoma) was supported by grants from the National Research Program on Genomic Medicine in Taiwan (DOH99-TD-G-111-028), the National Research Program for Biopharmaceuticals in Taiwan (MOHW 103-TDUPB-211-144003, MOST 103-2325-B-400-023) and the Bioinformatics Core Facility for Translational Medicine and Biotechnology Development (MOST 104-2319-B-400-002). This work was also supported by the Jinan Science Research Project Foundation (201102051), the National Key Scientific and Technological Project (2011ZX09307-001-04), the National Natural Science Foundation of China (No.81272293), the State Key Program of National Natural Science of China (81230067), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. NRF-2014R1A2A2A05003665), Sookmyung Women's University Research Grants, Korea (1-1603-2048), Agency for Science, Technology and Research (A*STAR), Singapore and the US National Institute of Health Grant (1U19CA148127-01). The overall GWAS project was supported by the intramural program of the US National Institutes of Health/National Cancer Institute. The following is a list of grants by study center: SKLCS (Y.T.K.)—National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2011-0016106). (J.C.) – This work was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (grant no. 0720550-2). (J.S.S.)—grant number is A010250. WLCS (T.W.)—National Key Basic Research and Development Program (2011CB503800). SLCS (B.Z.)—National Nature Science Foundation of China (81102194). Liaoning

Provincial Department of Education (LS2010168). China Medical Board (00726). GDS (Y.L.W.)—Foundation of Guangdong Science and Technology Department (2006B60101010, 2007A032000002, 2011A030400010). Guangzhou Science and Information Technology Bureau (2011Y2-00014). Chinese Lung Cancer Research Foundation, National Natural Science Foundation of China (81101549). Natural Science Foundation of Guangdong Province (S2011010000792). TLCS (K.C., B.Q.)—Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT), China (IRT1076). Tianjin Cancer Institute and Hospital. National Foundation for Cancer Research (US). FLCS (J.C.W., D.R., L.J.)—Ministry of Health (201002007). Ministry of Science and Technology (2011BAI09B00). National S&T Major Special Project (2011ZX09102-010-01). China National High-Tech Research and Development Program (2012AA02A517, 2012AA02A518). National Science Foundation of China (30890034). National Basic Research Program (2012CB944600). Scientific and Technological Support Plans from Jiangsu Province (BE2010715). NLCS (H.S.)—China National High-Tech Research and Development Program Grant (2009AA022705). Priority Academic Program Development of Jiangsu Higher Education Institution. National Key Basic Research Program Grant (2011CB503805). GEL-S (A.S.)—National Medical Research Council Singapore grant (NMRC/0897/2004, NMRC/1075/2006). (J.Liu)—Agency for Science, Technology and Research (A*STAR) of Singapore. GELAC (C.A.H.)—National Research Program on Genomic Medicine in Taiwan (DOH98-TDG-111-015). National Research Program for Biopharmaceuticals in Taiwan (DOH 100-TD-PB-111-TM013). National Science Council, Taiwan (NSC 100-2319-B-400-001). YLCS (Q.L.)—Supported by the intramural program of U.S. National Institutes of Health, National Cancer Institute. SWHS (W.Z., W-H.C., N.R.)—The work was supported by a grant from the National Institutes of Health (R37 CA70867, UM1 CA182910) and the National Cancer Institute intramural research program, including NCI Intramural Research Program contract (N02 CP1101066). JLCS (K.M., T.K.)—Grants-in-Aid from the Ministry of Health, Labor, and Welfare for Research on Applying Health Technology and for the 3rd-term Comprehensive 10-year Strategy for Cancer Control; by the National Cancer Center Research and Development Fund; by Grant-in-Aid for Scientific Research on Priority Areas and on Innovative Area from the Ministry of Education, Science, Sports, Culture and—Technology of Japan. (W.P.)—NCI R01-CA121210. HKS (J.W.)—General Research Fund of Research Grant Council, Hong Kong (781511 M). The Environment and Genetics in Lung Cancer Etiology (EAGLE), Prostate, Lung, Colon, Ovary Screening Trial (PLCO), and Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) studies were supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics. ATBC was also supported by U.S. Public Health Service contracts (N01-CN-45165, N01-RC-45035, and N01-RC-37004) from the NCI. PLCO was also supported by individual contracts from the NCI to the University of Colorado Denver (N01-CN-25514), Georgetown University (N01-CN-25522), the Pacific Health Research Institute (N01-CN-25515), the Henry Ford Health System (N01-CN-25512), the University of Minnesota, (N01-CN-25513), Washington University (N01-CN-25516), the University of Pittsburgh (N01-CN-25511), the University of Utah (N01-CN-25524), the Marshfield Clinic Research Foundation (N01-CN-25518), the University of Alabama at Birmingham (N01-CN-75022), Westat, Inc. (N01-CN-25476), and the University of California, Los Angeles (N01-CN-25404). The Carotene and Retinol Efficacy Trial (CARET) is funded by the National Cancer Institute, National Institutes of Health through grants U01-CA063673, UM1-CA167462, and U01-CA167462. The Cancer Prevention Study-II (CPS-II) Nutrition Cohort was supported by the American Cancer Society. The NIH Genes, Environment and Health Initiative (GEI) partly funded DNA extraction and statistical analyses (HG-06-033-NCI-01 and R01HL091172-01), genotyping at the Johns Hopkins University Center for Inherited Disease Research. This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea

government (MSIT) (No. 2020R1A2C4002236). Genotyping of the samples in NJLCS was supported by the National Natural Science of China (81820108028).

Female Lung Cancer Consortium in Asia (Tianjin): Tianjin Science and Technology Committee Foundation, 18YFZCSY00520.

Female Lung Cancer Consortium in Asia (Taiwan): The Ministry of Health and Welfare grants DOH97-TD-G-111-028 (I.S.C.), DOH98-TD-G-111-017 (I.S.C.), DOH99-TD-G-111-014 (I.S.C.); DOH97-TD-G-111-026 (C.A.H.), DOH98-TD-G-111-015 (C.A.H.), DOH99-TD-G-111-028 (C.A.H.); National Health Research Institutes grants NHRI-PH-110-GP-01, NHRI-PH-110-GP-03; and the Ministry of Science and Technology grants MOST108-2314-B-400-038(C.A.H.), MOST109-2740-B-400-002(C.A.H.).

The GWAS of lung cancer in European never smokers was supported by NIH R01 CA149462 (O.Y.G.).

OncoArray study in Europeans: The OncoArray data and analysis from INTEGRAL-ILCCO were supported by NIH U19 CA203654, and U19 CA148127. The data harmonization for ILCCO was supported by Canadian Institute for Health Research (CIHR) Canada Research Chair to R.J.H. and CIHR FDN 167273).

European never-smoking lung cancer study: C.I.A. is a Research Scholar of the Cancer Prevention Institute of Texas (CPRIT) and supported by CPRIT grant RR170048.

Taiwan eQTL study: This study was supported by the Ministry of Health and Welfare grants DOH97-TD-G-111-028 (I.S.C.), DOH98-TD-G-111-017 (I.S.C.), DOH99-TD-G-111-014 (I.S.C.); DOH97-TD-G-111-026 (C.A.H.), DOH98-TD-G-111-015 (C.A.H.), DOH99-TD-G-111-028 (C.A.H.); National Health Research Institutes grants NHRI-PH-110-GP-01, NHRI-PH-110-GP-03; and the Ministry of Science and Technology grants MOST108-2314-B-400-038(C.A.H.), MOST109-2740-B-400-002(C.A.H.).

N.C. is supported by NIH grant R01HG010480. P.Y. is supported by Mayo Clinic Foundation Research Funds, NIH-CA77118 and CA80127. G.L. is supported is supported by the Alan Brown Chair and Lusi Wong Fund of the Princess Margaret Cancer Foundation. D.C.C. is supported by U01CA209414. O.Y.G. is supported by NIH R01 CA231141.

Author contributions

Organized and designed the study: Q.L., J.S., N.R., J.C., S.J.C., N.C., K.S., K.M., T.K., M.T.L., C.I.A., O.Y.G., H.S., I-S.C., C.A.H., H.Shen. Conducted and supervised new genotyping for the project: K.S., K.M., T.K. Contributed to the design and execution of statistical analyses: J.S., J.C., S.J.C., N.R., Q.L., L.S., B.D.R., S.L., R.J.H., C.I.A., O.Y.G., N.C., I.S.C., K.M.F., K.S., K.M., T.K. W.J.S., T.Z., C.B., M.J.M., I.C., H.Shen. Wrote the first draft: J.S., J.C., N.R., Q.L., K.S., K.M., T-Y.C., J.D., R.J.H., K.C., N.C., O.Y.G., C.A.H., S.J.C., C.I.A., H.S., T.K., H.Shen. Conducted epidemiology studies and contributed samples to GWAS and/or conducted initial genotyping: Q.L., M.T.L., B.A.B., W.H., N.E.C., B.T.J., M.S., H.P., D.A., C.C., L.B., M.Y., A.H., B.H., J.Liu, B.Zhu, S.I.B., C.H.K., K.Wyatt, S.A.L., A.Chao, J.F.F.J., S.J.C., N.R., Z.Wang, C.L.W., J.C., C.W., W.T., D.Lin, S.J.A., X.C.Z., J.S., Y.L.W., M.P.W., L.P.C., J.C.M.H., V.H.F.L., Z.H., K.M., J.Y.P., Jia.Liu, H.S.J., J.E.C., Y.Y.C., H.N.K., M.H.S., S.S.K., Y.C.K., I.J.O., S.W.S., H.I.Y., Y.T.K., Y.C.H., J.H.K., Y.H.K., J.S.S., Y.J.J., K.H.P., C.H.K., J.S.K., I.K.P., B.S., Jie.Liu, Z.W., S.C., J.Y., J.W., Y.Y., Y.T.G., D.L., J.Y.Y.W., H.C., L.J., J.Z., G.J., K.F., Z.Y., B.Z., W.W., P.G., Q.H., X.L., Y.R., A.S., Y.L., Y.C., WY.L., W.Z., X.O.S., Q.C., G.Y., B.Q., T.W., H.G., L.L., P.X., F.W., G.W., J.X., J.L., R.C.H.V., B.B.,

H.D.H., Junwen W., J.Wang, A.D.L.S., J.K.C.C., V.L.S., K.C., H.Z., H.D., C.A.H., T-Y.C., L.H.C., I-S.C., C.Y.C., S.S.J., C.H.C., G.C.C., C.F.H., Y.H.T., W.C.W., K.Y.C., M.S.H., W.C.S., Y.M.C., C.L.W., K.C.C., C.J.Y., H.H.H., F.Y.T., H.C.L., C.J.C., P.C.Y., K.S., T.K., H.K., S.M., H.H., K.G., Y.O., S.W., Y.Yatabe, M.T., R.H., A.T., Y.M., M.K., Y.K., Y.D., Y.Miyagi, H.N., T.Y., N.S., M.I., M.H., Y.N., K.T., K.W., K.Matsuda, Y.Murakami, K.S., K.T., Y.O., M.S., H.S., A.G., Y.M., T.H., M.K., K.O., H.S., J.D., H.M., M.Z., R.J.H., S.L., A.T., C.C., S.E.B., M.Johansson, A.R., H.E.W., D.C.C., G.R., S.A., P.B., J.M.K., J.K.F., S.S.S., L.L.M., H.Bö., G.L., A.A., L.A.K., S.ZN., K.G., M.J., A.C., J.M.Y., P.L., M.B.S., M.C.A., C.I.A., A.G.S., R.H., M.R.S., O.Y.G., I.P.G., X.W., P.Y., J.Chang, M.Kobayashi, Y.Minamiya, K.Shimizu, M.Saito, Y.Ohtaki, K.Tanaka, J.Su, D.Lu, R.Houlston, S.Lam, A.Tardon, K.Grankvist, F.T., J.Wu, J.Li, H.Shen. All authors contributed to the writing and final review of the paper.

Funding

Open Access funding provided by the National Institutes of Health (NIH).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-023-38196-z>.

Correspondence and requests for materials should be addressed to Jianxin Shi or Qing Lan.

Peer review information *Nature Communications* thanks the anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023

Jianxin Shi ^{1,146} ✉, Kouya Shiraishi ^{2,146}, Jiyeon Choi ^{1,146}, Keitaro Matsuo ^{3,146}, Tzu-Yu Chen ^{4,146}, Juncheng Dai ^{5,6,146}, Rayjean J. Hung ^{7,146}, Kexin Chen ^{8,146}, Xiao-Ou Shu ^{9,146}, Young Tae Kim ¹⁰, Maria Teresa Landi¹, Dongxin Lin¹¹, Wei Zheng ⁹, Zhihua Yin¹², Baosen Zhou ¹³, Bao Song¹⁴, Jiucun Wang ^{15,16}, Wei Jie Seow^{1,17,18}, Lei Song¹, I-Shou Chang ¹⁹, Wei Hu¹, Li-Hsin Chien⁴, Qiuyin Cai ⁹, Yun-Chul Hong²⁰, Hee Nam Kim²¹, Yi-Long Wu ²²,

Maria Pik Wong²³, Brian Douglas Richardson^{1,24}, Karen M. Funderburk¹, Shilan Li^{1,25}, Tongwu Zhang¹, Charles Breeze¹, Zhaoming Wang²⁶, Batel Blechter¹, Bryan A. Bassig¹, Jin Hee Kim²⁷, Demetrius Albanes¹, Jason Y. Y. Wong¹, Min-Ho Shin²¹, Lap Ping Chung²³, Yang Yang²⁸, She-Juan An²², Hong Zheng⁸, Yasushi Yatabe²⁹, Xu-Chao Zhang²², Young-Chul Kim^{30,31}, Neil E. Caporaso¹, Jiang Chang³², James Chung Man Ho³³, Michiaki Kubo³⁴, Yataro Daigo^{35,36}, Minsun Song³⁷, Yukihide Momozawa³⁴, Yoichiro Kamatani³⁸, Masashi Kobayashi³⁹, Kenichi Okubo³⁹, Takayuki Honda⁴⁰, Dean H. Hosgood⁴¹, Hideo Kunitoh⁴², Harsh Patel¹, Shun-ichi Watanabe⁴³, Yohei Miyagi⁴⁴, Haruhiko Nakayama⁴⁵, Shingo Matsumoto⁴⁶, Hidehito Horinouchi⁴³, Masahiro Tsuboi⁴⁷, Ryuji Hamamoto⁴⁸, Koichi Goto⁴⁶, Yuichiro Ohe⁴³, Atsushi Takahashi³⁸, Akiteru Goto⁴⁹, Yoshihiro Minamiya⁵⁰, Megumi Hara⁵¹, Yuichiro Nishida⁵¹, Kenji Takeuchi⁵², Kenji Wakai⁵², Koichi Matsuda⁵³, Yoshinori Murakami⁵⁴, Kimihiro Shimizu⁵⁵, Hiroyuki Suzuki⁵⁶, Motonobu Saito⁵⁷, Yoichi Ohtaki⁵⁸, Kazumi Tanaka⁵⁸, Tangchun Wu⁵⁹, Fusheng Wei⁶⁰, Hongji Dai⁸, Mitchell J. Machiela¹, Jian Su²², Yeul Hong Kim⁶¹, In-Jae Oh^{30,31}, Victor Ho Fun Lee⁶², Gee-Chen Chang^{63,64,65,66}, Ying-Huang Tsai^{67,68}, Kuan-Yu Chen⁶⁹, Ming-Shyan Huang⁷⁰, Wu-Chou Su⁷¹, Yuh-Min Chen⁷², Adeline Seow¹⁷, Jae Yong Park⁷³, Sun-Seog Kweon^{21,74}, Kun-Chieh Chen⁶⁴, Yu-Tang Gao⁷⁵, Biyun Qian⁸, Chen Wu¹¹, Daru Lu^{15,16}, Jianjun Liu^{76,77}, Ann G. Schwartz⁷⁸, Richard Houlston⁷⁹, Margaret R. Spitz⁸⁰, Ivan P. Gorlov⁸⁰, Xifeng Wu⁸¹, Ping Yang⁸², Stephen Lam⁸³, Adonina Tardon⁸⁴, Chu Chen⁸⁵, Stig E. Bojesen^{86,87}, Mattias Johansson⁸⁸, Angela Risch^{89,90,91}, Heike Bickeböllner⁹², Bu-Tian Ji¹, H-Erich Wichmann^{93,94,95}, David C. Christiani⁹⁶, Gadi Rennert⁹⁷, Susanne Arnold⁹⁸, Paul Brennan⁸⁸, James McKay⁸⁸, John K. Field⁹⁹, Sanjay S. Shete¹⁰⁰, Loic Le Marchand¹⁰¹, Geoffrey Liu¹⁰², Angeline Andrew¹⁰³, Lambertus A. Kiemeny¹⁰⁴, Shan Zienoldiny-Narui¹⁰⁵, Kjell Grankvist¹⁰⁶, Mikael Johansson¹⁰⁷, Angela Cox¹⁰⁸, Fiona Taylor¹⁰⁸, Jian-Min Yuan¹⁰⁹, Philip Lazarus¹¹⁰, Matthew B. Schabath¹¹¹, Melinda C. Aldrich¹¹², Hyo-Sung Jeon¹¹³, Shih Sheng Jiang¹⁹, Jae Sook Sung⁶¹, Chung-Hsing Chen¹⁹, Chin-Fu Hsiao⁴, Yoo Jin Jung¹¹⁴, Huan Guo¹¹⁵, Zhibin Hu⁵, Laurie Burdett^{1,116}, Meredith Yeager^{1,116}, Amy Hutchinson^{1,116}, Belynda Hicks^{1,116}, Jia Liu^{1,116}, Bin Zhu^{1,116}, Sonja I. Berndt¹, Wei Wu¹², Junwen Wang^{117,118}, Yuqing Li¹¹⁹, Jin Eun Choi¹¹³, Kyong Hwa Park⁶¹, Sook Whan Sung¹²⁰, Li Liu¹²¹, Chang Hyun Kang¹¹⁴, Wen-Chang Wang¹²², Jun Xu¹²³, Peng Guan^{12,124}, Wen Tan¹¹, Chong-Jen Yu¹²⁵, Gong Yang⁹, Alan Dart Loon Sihoe¹²⁶, Ying Chen¹⁷, Yi Young Choi¹¹³, Jun Suk Kim¹²⁷, Ho-Il Yoon¹²⁸, In Kyu Park¹¹⁴, Ping Xu¹²⁹, Qincheng He¹², Chih-Liang Wang¹³⁰, Hsiao-Han Hung¹⁹, Roel C. H. Vermeulen¹³¹, Iona Cheng¹³², Junjie Wu^{15,16}, Wei-Yen Lim¹⁷, Fang-Yu Tsai¹⁹, John K. C. Chan¹³³, Jihua Li¹³⁴, Hongyan Chen^{15,16}, Hsien-Chih Lin⁴, Li Jin^{15,16}, Jie Liu¹⁴, Norie Sawada¹³⁵, Taiki Yamaji¹³⁶, Kathleen Wyatt^{1,116}, Shengchao A. Li^{1,116}, Hongxia Ma^{5,6}, Meng Zhu^{5,6}, Zhehai Wang¹⁴, Sensen Cheng¹⁴, Xuelian Li^{12,124}, Yangwu Ren^{12,124}, Ann Chao¹³⁷, Motoki Iwasaki^{135,136}, Junjie Zhu²⁸, Gening Jiang²⁸, Ke Fei²⁸, Guoping Wu⁶⁰, Chih-Yi Chen^{138,139}, Chien-Jen Chen¹⁴⁰, Pan-Chyr Yang¹⁴¹, Jinming Yu¹⁴, Victoria L. Stevens¹⁴², Joseph F. Fraumeni Jr¹, Nilanjan Chatterjee^{1,143,144,147}, Olga Y. Gorlova^{80,145,147}, Chao Agnes Hsiung^{4,147}, Christopher I. Amos^{80,145,147}, Hongbing Shen^{5,6,147}, Stephen J. Chanock^{1,147}, Nathaniel Rothman^{1,147}, Takashi Kohno^{2,147} & Qing Lan^{1,147} ✉

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. ²Division of Genome Biology, National Cancer Research Institute, Tokyo, Japan. ³Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan. ⁴Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan. ⁵Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. ⁶Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China. ⁷Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada. ⁸Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China. ⁹Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. ¹⁰Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. ¹¹Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ¹²Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China. ¹³Department of Clinical Epidemiology and Center of Evidence Based Medicine, The First Hospital of China Medical University, Shenyang, China. ¹⁴Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China. ¹⁵Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China. ¹⁶State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China. ¹⁷Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. ¹⁸Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore. ¹⁹National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan. ²⁰Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. ²¹Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea. ²²Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. ²³Department of Pathology, Queen Mary Hospital, Hong Kong, Hong Kong. ²⁴Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. ²⁵Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC, USA. ²⁶Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. ²⁷Department of Environmental Health, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea. ²⁸Shanghai Pulmonary Hospital, Shanghai, China. ²⁹Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. ³⁰Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasuneup, Republic of Korea. ³¹Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea. ³²Department of Etiology & Carcinogenesis, Cancer Institute

and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ³³Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong. ³⁴Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ³⁵Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ³⁶Department of Medical Oncology and Cancer Center, and Center for Advanced Medicine against Cancer, Shiga University of Medical Science, Shiga, Japan. ³⁷Department of Statistics & Research Institute of Natural Sciences, Sookmyung Women's University, Seoul, Republic of Korea. ³⁸Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ³⁹Department of Thoracic Surgery, Tokyo Medical and Dental University, Tokyo, Japan. ⁴⁰Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan. ⁴¹Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY, USA. ⁴²Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan. ⁴³Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. ⁴⁴Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan. ⁴⁵Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. ⁴⁶Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. ⁴⁷Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan. ⁴⁸Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan. ⁴⁹Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan. ⁵⁰Department of Thoracic Surgery, Graduate School of Medicine, Akita University, Akita, Japan. ⁵¹Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan. ⁵²Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. ⁵³Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ⁵⁴Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ⁵⁵Department of Surgery, Division of General Thoracic Surgery, Shinshu University School of Medicine Asahi, Nagano, Japan. ⁵⁶Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan. ⁵⁷Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan. ⁵⁸Department of Integrative center of General Surgery, Gunma University Hospital, Gunma, Japan. ⁵⁹Institute of Occupational Medicine and Ministry of Education Key Lab for Environment and Health, School of Public Health, Huazhong University of Science and Technology, Wuhan, China. ⁶⁰China National Environmental Monitoring Center, Beijing, China. ⁶¹Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea. ⁶²Department of Clinical Oncology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong. ⁶³School of Medicine and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. ⁶⁴Department of Internal Medicine, Division of Pulmonary Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. ⁶⁵Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan. ⁶⁶Department of Internal Medicine, Division of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. ⁶⁷Department of Respiratory Therapy, Chang Gung University, Taoyuan, Taiwan. ⁶⁸Department of Pulmonary and Critical Care, Xiamen Chang Gung Hospital, Xiamen, China. ⁶⁹Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan. ⁷⁰Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University and Kaohsiung Medical University, Kaohsiung, Taiwan. ⁷¹Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. ⁷²Department of Chest Medicine, Taipei Veterans General Hospital, and school of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ⁷³Lung Cancer Center, Kyungpook National University Medical Center, Daegu, Republic of Korea. ⁷⁴Jeonnam Regional Cancer Center, Chonnam National University, Hwasun, Republic of Korea. ⁷⁵Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China. ⁷⁶Genome Institute of Singapore, Agency of Science, Technology and Research, Singapore, Singapore. ⁷⁷Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ⁷⁸Karmanos Cancer Institute, Detroit, MI, USA. ⁷⁹Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. ⁸⁰Department of Medicine, Section of Epidemiology and Population Science, Institute for Clinical and Translational Research, Houston, TX, USA. ⁸¹School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. ⁸²Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. ⁸³British Columbia Cancer Agency, Vancouver, BC, Canada. ⁸⁴IUOPA, University of Oviedo and CIBERESP, Madrid, Spain. ⁸⁵Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ⁸⁶Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁸⁷Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark. ⁸⁸International Agency for Research on Cancer (IARC/WHO), Lyon, France. ⁸⁹German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁹⁰Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany. ⁹¹University of Salzburg and Cancer Cluster Salzburg, Salzburg, Austria. ⁹²University Medical Center Goettingen, Goettingen, Germany. ⁹³Institute of Medical Informatics, Biometry and Epidemiology, Ludwig Maximilians University, Munich, Germany. ⁹⁴Helmholtz Center Munich, Institute of Epidemiology, Munich, Germany. ⁹⁵Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany. ⁹⁶Harvard TH Chan School of Public Health, Boston, MA, USA. ⁹⁷Carmel Medical Center, Haifa, Israel. ⁹⁸Markey Cancer Center, Lexington, KY, USA. ⁹⁹Liverpool University, Liverpool, UK. ¹⁰⁰The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ¹⁰¹Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA. ¹⁰²Princess Margaret Cancer Center, Toronto, ON, Canada. ¹⁰³Norris Cotton Cancer Center, Lebanon, NH, USA. ¹⁰⁴Radboud University Medical Center, Nijmegen, Netherlands. ¹⁰⁵National Institute of Occupational Health, Oslo, Norway. ¹⁰⁶Department of Medical Biosciences, Umeå University, Umeå, Sweden. ¹⁰⁷Department of Radiation Sciences, Umeå University, Umeå, Sweden. ¹⁰⁸University of Sheffield, Sheffield, UK. ¹⁰⁹UPMC Hillman Cancer Center and Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. ¹¹⁰Washington State University College of Pharmacy, Spokane, WA, USA. ¹¹¹Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. ¹¹²Department of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA. ¹¹³Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea. ¹¹⁴Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. ¹¹⁵Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ¹¹⁶Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Rockville, MD, USA. ¹¹⁷Department of Biochemistry, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ¹¹⁸Centre for Genomic Sciences, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ¹¹⁹Department of Human Genetics, Genome Institute of Singapore, Singapore, Singapore. ¹²⁰Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. ¹²¹Department of Oncology, Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, China. ¹²²The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. ¹²³School of Public Health, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ¹²⁴Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, China. ¹²⁵Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. ¹²⁶Gleneagles Hong Kong Hospital, Hong Kong, China. ¹²⁷Department of Internal Medicine, Division of Medical Oncology, College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea. ¹²⁸Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. ¹²⁹Department of Oncology, Wuhan Iron and Steel (Group) Corporation Staff-Worker Hospital, Wuhan, China. ¹³⁰Department of Pulmonary and Critical Care, Chang Gung Memorial Hospital, Taoyuan, Taiwan. ¹³¹Division of Environmental

Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands. ¹³²Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. ¹³³Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China. ¹³⁴Qujing Center for Diseases Control and Prevention, Qujing, China. ¹³⁵Division of Cohort Research, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan. ¹³⁶Division of Epidemiology, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan. ¹³⁷Center for Global Health, National Cancer Institute, Bethesda, MD, USA. ¹³⁸Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. ¹³⁹Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan. ¹⁴⁰Genomic Research Center, Academia Sinica, Taipei, Taiwan. ¹⁴¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. ¹⁴²Laboratory Services, American Cancer Society, Atlanta, GA, USA. ¹⁴³Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. ¹⁴⁴Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ¹⁴⁵Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. ¹⁴⁶These authors contributed equally: Jianxin Shi, Kouya Shiraishi, Jiyeon Choi, Keitaro Matsuo, Tzu-Yu Chen, Juncheng Dai, Rayjean J Hung, Kexin Chen, Xiao-Ou Shu ¹⁴⁷These authors jointly supervised this work: Nilanjan Chatterjee, Olga Y. Gorlova, Chao Agnes Hsiung, Christopher I. Amos, Hongbing Shen, Stephen J. Chanock, Nathaniel Rothman, Takashi Kohno, Qing Lan. ✉e-mail: jianxin.shi@nih.gov; qingl@mail.nih.gov